NCP Flanders
choose your programme
Horizon Europe

Horizon Europe is the main Research and Innovation Funding Programme of the European Commission.

Horizon 2020

Horizon 2020 is the previous Funding Programme. There are no longer calls, but projects can run until 2024.

Digital Europe

Digital Europe is a Funding Programme focused on bringing digital technology to businesses, citizens and administrations.

Other EU Funding

There are many other relevant EU funding programmes, managed by several agencies and directorates.

Event Calendar

Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020

European Innovation Council Pathfinder and Transition calls Info session

MAY
Wed
05
13:30 - 15:30

This was 2 years ago

Location

virtual

Programmes

The slides and recording are now available in our video corner.

Under the European Innovation Council (EIC) Pathfinder and Transition schemes there are Open calls and Challenge driven calls. Under Open calls any topic can be submitted (thus bottom-up), under the Challenges topics are prescribed. The Pathfinder Open is for consortia of at least 3 different independent legal entities (e.g. universities, research organisations, industry and SMEs) in at least 3 eligible countries. The Pathfinder Challenges are for single entities or small consortia. Grants go up to 3 million Euro (Open) or 4 million Euro (Challenges).

The EIC Transition is for SMEs, spin-offs, start-ups, research organisations and universities applying either individually or in small consortia from 2 to 5 partners. Proposals must build upon results from ERC Proof of Concept projects, Future and Emerging Technologies (FET) or EIC Pathfinder projects. Grants go up to 2.5 million Euro. Details can be found in the EIC work programme 2021.

The EIC Pathfinder and Transition calls will be presented by Bart Van Caenegem, Head of Sector EIC Challenge-based Pathfinder of the European Innovation Council and SMEs Executive Agency (EISMEA) and the testimony by professor Marc Elskens of the laboratory for Analytical, Environmental and Geo-Chemistry of the Vrije Universiteit Brussel (VUB-AMGC).

Programme

13.30 Welcome

13.35 Overview of the EIC objectives and key aspects

13.45 Pathfinder Open + Q&A  

14.15 Pathfinder Challenges + Q&A

14.30 Transition Open and Transition Challenges + Q&A

15.00 Testimony Horizon2020 FET Open RIA project “TriboREMEDY” + Q&A

15.20 Closure

(Language: English)

Targeted public: stakeholders located in Flanders. Participation is free but registration is required through this registration form. The log-in instructions to the webinar (by GoToWebinar platform) will be send from the day before the webinar onwards.

More information on the info session on EIC Accelerator on the third of May can be found here.

myOVERVIEW
- sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon 2020 & Horizon Europe.

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.